Publications by authors named "Clemens Giessen"

Claim this Profile
N
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Christoph Schulz, Frank Kullmann, Volker Kunzmann, Martin Fuchs, Michael Geissler, Clemens Giessen

Int J Cancer· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3.
Michael Haas, Christoph Kern, Stephan Kruger, Marlies Michl, Dominik P Modest, Clemens Giessen

Tumour Biol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
Sebastian Gamba, Peter Camaj, Volker Heinemann, Rüdiger P Laubender, Yan Wang, Clemens Giessen

Anticancer Drugs· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials.
Clemens Giessen, Ruediger Paul Laubender, Donna Pauler Ankerst, Sebastian Stintzing, Dominik Paul Modest

Acta Oncol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient.
Nikolaus Kneidinger, Clemens Giessen, Werner von Wulffen, Katrin Milger, René Schramm

Int J Infect Dis· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer.
Clemens Giessen, Dorothea Nagel, Maria Glas, Fritz Spelsberg, Ulla Lau-Werner

Tumour Biol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
Dominik P Modest, Christoph Schulz, Ludwig F von Weikersthal, Detlef Quietzsch, Jobst C von Einem, Clemens Giessen

Anticancer Drugs· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels.
Sebastian Stintzing, Doris Fischhaber, Charlotte Mook, Dominik P Modest, Clemens Giessen

Anticancer Drugs· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial.
Dominik P Modest, Ruediger P Laubender, Sebastian Stintzing, Clemens Giessen, Christoph Schulz

Acta Oncol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial.
Clemens Giessen, Ruediger P Laubender, Ludwig Fischer von Weikersthal, Andreas Schalhorn, Dominik P Modest

Cancer Sci· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined resection of colorectal hepatic-pulmonary metastases shows improved outcome over chemotherapy alone.
Georgios Meimarakis, Martin Angele, Claudius Conrad, Rolf Schauer, Rolf Weidenhagen, Clemens Giessen

Langenbecks Arch Surg· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.
Sebastian Stintzing, Christine Kapaun, Rüdiger Paul Laubender, Andreas Jung, Jens Neumann, Clemens Giessen

Int J Cancer· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.
Clemens Giessen, Ruediger Paul Laubender, Donna Pauler Ankerst, Sebastian Stintzing, Dominik Paul Modest

Clin Cancer Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Dominik Paul Modest, Anke Reinacher-Schick, Sebastian Stintzing, Clemens Giessen, Andrea Tannapfel

Anticancer Drugs· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary effusion lymphoma (PEL) without effusion: a patient case report of a PEL solid variant.
Clemens Giessen, Dorit Di Gioia, Bruno Huber, Bettina Seppi, Anno Graser

J Clin Pathol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
Clemens Giessen, Sebastian Stintzing, Ruediger Paul Laubender, Donna Pauler Ankerst, Christoph Schulz

Clin Colorectal Cancer· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
Dominik P Modest, Sebastian Stintzing, Ruediger P Laubender, Jens Neumann, Andreas Jung, Clemens Giessen

Anticancer Drugs· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Colon cancer: adjuvant chemotherapy and aftercare].
Volker Heinemann, Clemens Giessen, Dominik Modest, Nicolas Moosmann, Sebastian Stintzing

MMW Fortschr Med· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, Sebastian Stintzing, Frank Kullmann

BMC Cancer· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Ludwig Fischer von Weikersthal, Andreas Schalhorn, Martina Stauch, Detlef Quietzsch, Peter A Maubach, Clemens Giessen

Eur J Cancer· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
Christoph Schulz, Volker Heinemann, Andreas Schalhorn, Nikolas Moosmann, Thomas Zwingers, Clemens Giessen

World J Gastroenterol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis